A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Given the promising activity of capecitabine and vinorelbine in metastatic breast cancer, this randomized phase II trial evaluated the efficacy and safety of this combination as neoadjuvant chemotherapy in breast cancer. Materials and Methods Patients with operable breast cancer (n=75) were randomly assigned to receive either four cycles of adriamycin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks followed by four cycles of docetaxel 75 mg/m2 every 3 weeks (AC-D) or four cycles of capecitabine 2,000 mg/m2 (day 1-14) plus vinorelbine 25 mg/m2 (days 1 and 8) every 3 weeks followed by four cycles of docetaxel 75 mg/m2 (CV-D). The primary endpoint was pathologic complete response (pCR) in the primary breast (ypT0/is). Results Most patients (84%) had locally advanced (n=41) or inflammatory breast cancer (n=22). pCR rates in the primary breast were 15% (95% confidence interval [CI], 7% to 30%) and 11% (95% CI, 4% to 26%) in the AC-D and CV-D groups, respectively. The overall response rates and 5-year progression-free survival rates in the AC-D and CV-D groups were 62% and 64%, and 51.3% (95% CI, 34.6% to 68.0%) and 30.2% (95% CI, 13.3% to 47.1%), respectively. Although both regimens were well tolerated, CV-D showed less frequent grade 3-4 neutropenia and vomiting than AC-D, whereas manageable diarrhea and hand-foot syndrome were more common in the CV-D group. Conclusion CV-D is a feasible and active non-anthracycline–based neoadjuvant chemotherapy regimen for breast cancer.
Abstract
Purpose Given the promising activity of capecitabine and vinorelbine in metastatic breast cancer, this randomized phase II trial evaluated the efficacy and safety of this combination as neoadjuvant chemotherapy in breast cancer. Materials and Methods Patients with operable breast cancer (n=75) were randomly assigned to receive either four cycles of adriamycin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks followed by four cycles of docetaxel 75 mg/m2 every 3 weeks (AC-D) or four cycles of capecitabine 2,000 mg/m2 (day 1-14) plus vinorelbine 25 mg/m2 (days 1 and 8) every 3 weeks followed by four cycles of docetaxel 75 mg/m2 (CV-D). The primary endpoint was pathologic complete response (pCR) in the primary breast (ypT0/is). Results Most patients (84%) had locally advanced (n=41) or inflammatory breast cancer (n=22). pCR rates in the primary breast were 15% (95% confidence interval [CI], 7% to 30%) and 11% (95% CI, 4% to 26%) in the AC-D and CV-D groups, respectively. The overall response rates and 5-year progression-free survival rates in the AC-D and CV-D groups were 62% and 64%, and 51.3% (95% CI, 34.6% to 68.0%) and 30.2% (95% CI, 13.3% to 47.1%), respectively. Although both regimens were well tolerated, CV-D showed less frequent grade 3-4 neutropenia and vomiting than AC-D, whereas manageable diarrhea and hand-foot syndrome were more common in the CV-D group. Conclusion CV-D is a feasible and active non-anthracycline–based neoadjuvant chemotherapy regimen for breast cancer.
참고문헌 (25)
- Schwartz GF, "Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast", Cancer, 73, pp.362~369 (1994)
- Mauriac L, "Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm : results of a randomized trial in a single centre", Ann Oncol, 2, pp.347~354 (1991)
- van der Hage JA, "Preoperative chemotherapy in primary operable breast cancer : results from the European Organization for Research and Treatment of Cancer trial 10902", J Clin Oncol, 19, pp.4224~4237 (2001)
- Rastogi P, "Preoperative chemotherapy : updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27", J Clin Oncol, 26, pp.778~785 (2008)
- Martin M, "Adjuvant docetaxel for node-positive breast cancer", N Engl J Med, 352, pp.2302~2313 (2005)
- Mackey JR, "Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer : 10-year follow-up of the phase 3 randomised BCIRG 001 trial", Lancet Oncol, 14, pp.72~80 (2013)
- Bear HD, "Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National Surgical Adjuvant Breast and Bowel Project Protocol B-27", J Clin Oncol, 24, pp.2019~2027 (2006)
- Henderson IC, "Can we abandon anthracyclines for early breast cancer patients?", Oncology (Williston Park), 25, pp.115~127 (2011)
- Giordano SH, "Decline in the use of anthracyclines for breast cancer", J Clin Oncol, 30, pp.2232~2239 (2012)
- Wildiers H, "Neoadjuvant capecitabine and docetaxel(plus trastuzumab) : an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer", Ann Oncol, 22, pp.588~594 (2011)
- Lee KS, "A randomized phase-III trial of docetaxel", capecitabine versus doxorubicin, III breast cancer, pp.Breast Cancer Res Treat, 2008[DOI]
- Jones SE, "Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer", J Clin Oncol, 24, pp.5381~5387 (2006)
- Chan A, "Capecitabine and vinorelbine in metastatic breast cancer", Eur J Cancer, 45, pp.2253~2265 (2009)
- Pajk B, "Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline-and taxane-pretreated metastatic breast cancer : findings from the EORTC 10001 randomized phase II trial", Breast, 17, pp.180~185 (2008)
- Sawada N, "Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models", Proc Am Assoc Cancer Res, 43, pp.1088~ (2002)
- Ahn Jin Hee, "Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane", Journal of Korean Medical Science, 19(4), pp.547~553 (2004), 대한의학회
- Welt A, "Phase I", II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer, 2005, pp.16, 64~69
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors : European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Simon R, "Optimal two-stage designs for phase II clinical trials", Control Clin Trials, 10, pp.1~10 (1989)
- von Minckwitz G, "Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer : phase III randomized GeparTrio trial", J Natl Cancer Inst, 100, pp.542~551 (2008)
- 유창훈, "Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy", Journal of Breast Cancer, 15(2), pp.203~210 (2012), 한국유방암학회[DOI]
- Andre F, "HER2 expression and efficacy of preoperative paclitaxel", FAC chemotherapy in breast cancer, 2008, pp.108, 183~190
- Kuerer HM, "Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy", J Clin Oncol, 17, pp.460~469 (1999)
- Ring AE, "Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer", Br J Cancer, 91, pp.2012~2017 (2004)
- von Minckwitz G, "Response-guided neoadjuvant chemotherapy for breast cancer", J Clin Oncol, 31, pp.3623~3630 (2013)